and Thank everyone. you, Mike, good afternoon,
earnings strong in our base best-in-class guidance. the rates. with results non-GAAP our Organic results businesses discuss $X.XX, for as We were of $X.XX to revenue by financial recovery to COVID-XX excellent continued quarter doubled, the was contributions line share as fight. per by billion Total our We driven well in growth are momentum and financial our fiscal both pleased second overall, highlighted revenue and XXXX. posted
On the quadrupled. EPS more line, bottom than
guidance the rates enabled even in to meet value as our again overall Our second its expected. our us sales less assay in business were diversified businesses core model than quarter though demonstrated COVID strong growth
finished like slightly diversification Diagnostics led for Our base a driven our the big possible terms: in out When discuss business set revenue things we the while more against pandemic even I as company. forecast, we Health a two U.S. to committed and and does, as emerge us she a has our ensure by topics. two a faster-than-expected primary pandemic. January before an COVID first, pandemic impact that recovery. increasing And than overcoming began would better outperformed clearly utilization And from strategy division was Healthcare helped to to the Karleen will franchise, simple took both than as Surgical ago, COVID details. year cases. every accomplish as Breast make our expense second, the we tough stronger to to action But we that cover wanted
accomplishing future. makes which goals, about excited We us more are clearly both ever than our
In our terms pandemic a first scale. goal, on fight the helping global of
our key by summarize focusing four Let’s on numbers. contributions
million. first Our XXX number is
the in test total ship diagnostics millionth commitment time, included production molecular our have million we the customers, Women’s maintained our we provide will COVID capacity. test quarter. second which Soon, XX XXX increasing dramatically Health At by to same to
portfolio million Manchester, U.K. expansion XXXX. the make tests on-track by Diego XX are We of in with plans San at quarter to January a our and least capacity to our have across
COVID growth our million sales even of total a and to second tremendous in which countries other XX. These with testing prospects relationships tests number future is our market $XXX is which quarter, franchises. of the international customers, been represented and our continues for COVID to global business, battle to diagnostics contributed in our in have continues the This be Our sold we strengthen COVID crisis. what has second international help access number of revenue as we XXX%.
Our global year, over to we have the number shipped the is Panther second instruments is last XXX. quarter. the including This about customers of third number XXX in
shipped COVID, in an of average reminder, five-years we year. XXX a As a Panthers the before
more last XX-months. that the tripled pace So we have over than
year. appreciate for $X.XX roughly when addition, has last these the our In second significantly quarter. our are us as us This remains has of record new high have are And COVID platform while is deal this billion. expect sign Panthers on to total XX% our for we seeing million capabilities. than fiscal as on contributed enabled Overall, over And non-COVID come approximately a base placements. last sheet. operating and nearly all we This we now instruments, installed companies customers four a of future a the robust very giving to have strengthening flow basis we system’s fourth for pandemic for to fifth, $XXX Panthers. discussed, since very encouraged out assay even stands record lead All billion that began, demand to acquire business is further began, XXXX, pandemic the exceed in we the growth these the a revenue balance higher global which including and number, $X.X more year’s cash levels our global at generated best-in-class numbers play with of to this X,XXX
business development minute. our activity more discuss in a will We
high, many that expire. up in to products their before at the helping are are market installed continue Customers that to they accommodate than public industry-wide have of declined significantly wanted higher the so-called a COVID have remain infection supported Panther testing our rollout. better-than-expected performed that clinical for platforms. to further Customers see, than April. demand. tests on of that likely choice into assay March do publicly AdvaMed back context, data demand with the base remain of to uniquely the other COVID patient This and share. multiple now is vaccine in these the will for using need two But consolidate many of inventory intend dynamic in we that January gain is sales remain remain believe In any ways less higher diagnosis, COVID testing highly them running important our This test. tests tests decline quarter. reflects molecular value and molecular as we provide since pivoted based close the Hologic We reopen tests the tell on in this down. automated and pandemic performance that needed that U.S., economies. they vaccines to on further but and impact significantly believe you us gold-standard its But in Based assays life to accurate levels indicating accumulated of unpredictable. that being for manufacturers molecular our we understanding facilities available for the out, very Panther the worked and U.S. of Aptima testing have also which us positioned volumes response ongoing testing testing in COVID you further roll In had and shipped, to much our beyond. to that, we changes, and current ahead data second perspective is purposes on fiscal winter all to XXXX changes seen, market on that the market control Before of when by declined the the show these they
about tests base in testing in results customers labs turnaround highly patients, has test XX-years. Combo clinical bring the want with positioned First, are sell, U.S. closer three first been by on XXX Notably, on is well which relevance. their United selling hospital means second for tests times delivered This our COVID to being Panthers only Aptima more COVID who COVID improving test being the now more clinical market to that to and run this decentralized Panther accurate that for the we than States. most X, roughly in is following hours.
more Second, by tests we internationally. selling pivoted
seen the of has paces the increasing importance news, struggled vaccine with in rollout at around everyone inoculations, Europe, particular, the different testing. is world. proceeding has in the As
United assay mainly from in almost of States, the example, Europe. COVID from quarter, For our came outside second revenue the XX%
gears for of the shift other our tremendous on to have the COVID made second against update major an the impact we pandemic. has side business our let’s Now topic, how strengthened
before As our steadily the had X% new pandemic on acquisitions. improving based products, will recall, hit, been organic to international many early our growth rate around you of and expansion
deals broader, and Diagenode, our tests in long-standing million strategic Belgian Diagnostics, COVID with buying closed it Panther will A in of after of enabling in diagnostic the we that very become our for we annual adjacent a since acquisition growth complete to the leader. of off leader our Cancer zero well, and confident our enable base molecular acquired a begin years, develop the We treatment offer since business. accelerating diagnostic exactly expand Biotheranostics, know developer to capabilities acquired manufacturer tests diversified development late that benefit strong million we $XX cancers, But us Diagenode’s therapies. of instrument. process, molecular approximately the of several generated assay to dramatically more February, more to Diagenode, hit. broaden to based Breast is are be cash February, have we more $XXX two predict mainly our for in manufacture the in we COVID us oncology. bases endocrine a assets a planning we by extended test business fully goal $XXX and XXXX, partnered XXXX organic epigenetics market year, a growing pandemic and higher for Diagnostics. last Fusion. breast assays completed inclusion assays closed into than Now than on guidelines This have in since to faster Biotheranostics, menu we sales, we the metastatic automated had for In differentiated million. assay Since used our products excluding as days growth third, high-throughput In NCCN to a the PCR molecular Gen-Probe Index was them diagnostics start, before we with of have which are portfolio acquisition the next flows Fusion will companies and on revenue than few of announced
As you one we ability the developed the PCR reasons years external might ago. was leverage system the of recall, expertise Fusion to
many available of efforts make PCR CE accelerate that is we our their growth. Mark assay of enhancing further tests European Now Diagenode on unique development part platform, can Hologic, and those
for Mobidiag, Finnish Fusion a developer this decade. innovative contrast diagnostics Mobidiag month, to announced we agreement our helps new earlier a instrumentation In Diagenode, we been leverage world, interested base Finally, installed in molecular which tests around than the our acquire more capabilities that us brings million. have and approximately $XXX of for to
market This encompasses truly ease is area an for infections a gastrointestinal limited that care Mobidiag presence care-associated in Mobidiag’s assay don’t generated acute space United in in resistance Novodiag respiratory unique differentiated a in Having with more innovator and Specifically, no test rapid growing health antibiotic years, near-patient we this over calendar rapidly and use, believe of Mobidiag large, of turnaround, low among with combination States. million we closely today. is XXXX conditions, others. a cost. monitored of compete multiplexing a $XX the sales and the revenue than commercial and platform diagnostics,
we we here. States assays in globally, but United accelerate So get their believe some we of once can growth their the especially approved
call patient how during also continued Breast briefly to touch on the our over wanted Karleen, pandemic. Before the businesses we I strengthened to I In Surgical have have diversify Breast, and we to turn portfolio service. continuum a interventional strategy the equipment, business software our on of hardware upgrades, the and care. capital sell full We across and tools expand of now to
have understandably we customers. COVID, has the While our world Health increased on presence been Breast with direct focused
based breast launched longtime we these very artificial global our We in doing well, partner cancer Health quarter with products outperform buying growth helped second strategies franchise of a Brevera, and exceeding SOMATEX, And levels by Together, Breast our all XXXX of developer leading the is total and on strengthened investments sales X.X%. have markers. have software re-launching new intelligence. which and interventional in
growth sell with our the business levels, we market mammography productive. pleased our position to and are highly-engaged quite Broadening portfolio outlook the Surgical, have R&D not been a In competitive that both is for we pipelines the future. sales pre-COVID back high-performing, through While development force. of very and products
and New product, MyoSure laparoscopic System, such Management are and our our ProVu Fluent Acessa’s market-leading hysteroscopes products Fluid new complementing devices. RF NovaSure as
a Surgical and result, by regions global that a the levels even overcoming from January second a that in hard surpassed quarter while were X.X% sales resulted on As COVID. procedures XXXX slow grew in reduced U.S. hit basis,
our have or never state confident conclusion, I future. I that in to been So in more want excited emphatically
have there fashion the continue have we one testing remarkable needs responded COVID importantly, testing to world. I’m geography every Even multiple team quarters strengthened done, literally the every company We to world’s for and and need our be will our in more around in truly for and our ahead. a the to of the businesses has years look growth at amazed really platforms we during added new what last forward XX-months. and to
Now call I to will the Karleen. turn over
